BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.

Original reporting
Published Nov 5, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary — source image
Decision brief

The 30-second read

$BIOABearishMed
01

Why it matters

The earnings miss deepens the company's cash‑burn profile, likely prompting short‑term price declines.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech sector risk and cash‑flow dynamics.

03

What to watch

The $0.9M increase in Novartis funding cap may provide runway despite current short‑term loss.

Relevance 7/10Novelty 8/10Timing: post‑market filing

Background

BioAge Labs is a clinical‑stage biotech focused on aging therapeutics. The 10‑Q filing provides the first public disclosure of Q3 2026 results.

Company-level read

Ticker impact

$BIOABearishMedium confidence
Context

BioAge Labs reported Q3 2026 revenue of $298K, an 85% YoY decline, and a net loss of $33.5M, widening 66% YoY.

Expected impact

likely pressure as the market prices in the revenue collapse and loss expansion

Evidence & confidence

Earnings miss on both top and bottom line for a micro‑cap biotech typically triggers sell‑offs, especially with increased R&D spend and no offsetting news.

Market effects

May weigh on other early‑stage biotech stocks as investors reassess cash‑burn expectations.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the Novartis collaboration expands further, the cash burn could translate into future upside.

Key entities

  • BioAge Labs, Inc.

    US‑listed biotech reporting Q3 2026 results.

  • Novartis

    Collaboration partner providing research funding.

Related articles

$BIOAMedAI 8/10

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMed

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

$BIOAMed

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.

$BIOAMedAI 8/10

BioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily…

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events BioAge Labs, Inc. (the “ Company ”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“ DME ”), an